Moonwalk Biosciences is developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases. The Company's proprietary AI-enabled discovery platform integrates human genetics, epigenomics and multi-omics with adipose-selective siRNA chemistry to identify and validate novel therapeutic targets involved in adipose biology, without affecting appetite. Moonwalk is advancing a pipeline of therapies designed to preserve lean mass, improve tolerability and enable infrequent dosing while addressing the underlying biology of obesity and metabolic disease.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
09/08/26	$70,000,000	Series B	Alpha Wave ARCH Venture Partners Eli Lilly and Company Future Ventures Gaorong Capital Khosla Ventures YK Bioventures	undisclosed